Nanotechnology Now

Heifer International

Wikipedia Affiliate Button


Home > Press > Toumaz Technology Secures Future Funding

Toumaz Technology becomes wholly-owned subsidiary of AIM-listed Nanoscience Inc.

Major new funding to create jobs in engineering and commercial teams

Toumaz Technology Secures Future Funding for Product Develop

Abingdon, United Kingdom | Posted on November 04, 2005

Toumaz Technology Limited today announces that its acquisition by the nanotechnology investment vehicle Nanoscience Inc., has formally completed, with the associated placing of Nanoscience shares raising £7.1 million (approximately £6.4 million net of expenses). Toumaz is now a wholly-owned subsidiary of the AIM listed Nanoscience. The consideration payable in respect of the acquisition has been satisfied through the issue of 96,337,210 Nanoscience shares, valuing Toumaz at approximately £17.7 million. Toumaz will retain its independent commercial identity while being able to take advantage of the benefits of being part of a stronger enlarged publicly listed entity.

The strategic focus for Toumaz remains unchanged but the transaction will enable Toumaz to accelerate the ongoing development of its ultra-low power Sensium family of devices based on the company’s proprietary AMx™ advanced mixed signal technology. Toumaz’s close links with Imperial College, London ­ with which it has a technology pipeline agreement ­ have recently been strengthened by the co-founding of the new Institute of Biomedical Engineering by the company’s Chairman and CTO, Professor Chris Toumazou, giving Toumaz the opportunity to access the major global pharmaceutical and medical device manufacturers.

Professor Chris Toumazou, newly appointed Non-Executive Director of Nanoscience, commented on the strengthened relationship with Imperial College, “With the New IP Option Agreement with Imperial Innovations, Toumaz has been granted the exclusive right to explore the commercial potential of intellectual property generated within the new Institute of Biomedical Engineering in the field of wireless communications and low power circuit design.”

Toumaz plans to invest part of the funds raised in a number of key areas, including ongoing new product development, support for further investigations into advanced semiconductor processes and the strengthening of the company’s engineering and commercial teams.

Commenting on today’s announcement, Richard Rose, Non-Executive Chairman of Nanoscience, said, “It is my belief that this acquisition marks a significant and substantial progressive step for both parties. Toumaz will bring to Nanoscience two key elements: the first being a world-leading technology with a number of established and identified target markets ranging from healthcare to consumer electronics; and the second being a significant base of industry and academic contacts that will be key to the procurement of further technologies and the establishment of collaborative product development projects.”

Keith Errey, CEO of Toumaz Technology, added, “This acquisition combines a fantastic technical team in Toumaz with a very accomplished commercial team in Nanoscience. By enabling us to leverage Nanoscience’s wide commercial expertise and investor experience, this route will allow Toumaz to remain focused on our technology development and the execution of that technology ­ our core business. We believe that the combined strengths of the companies will create an entity of significant value.”


About Toumaz Technology:
Toumaz Technology Limited is a developer of advanced RF, analogue and mixed signal semiconductors. The focus of the business is low power devices based on the company’s proprietary AMx™ (Advanced Mixed Signal) technology which addresses the needs of lower power consumption for mobile and wirelessly connected systems.

For more information, please click here

About Nanoscience Inc.:
Nanoscience is a specialist investment vehicle which listed on the AIM Market of the London Stock Exchange in March of this year with the specific intention of gaining exposure for investors to the rapidly emerging global nanotechnology sector, as well as becoming a de facto route to investment for near-revenue SME nanotechnology companies.

Nicky Davis
+44 (0) 7747 017654

Copyright © Toumaz Technology

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015

Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015

Graphenea embarks on a new era April 16th, 2015

Harris & Harris Group Portfolio Company OpGen Files Amended Registration Statement for Proposed Public Offering April 8th, 2015


Nanotech-enabled moisturizer speeds healing of diabetic skin wounds: Spherical nucleic acids silence gene that interferes with wound healing April 24th, 2015

Fast and accurate 3-D imaging technique to track optically trapped particles April 24th, 2015

Pseudoparticles travel through photoactive material: KIT scientists measure important process in the conversion of light energy -- publication in Nature Communications April 24th, 2015

Surface matters: Huge reduction of heat conduction observed in flat silicon channels April 23rd, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project